Lilly's Omvoh meets primary endpoint in pediatric ulcerative colitis
FROM THE WIRE · FINANCE.YAHOO.COM
Building on Omvoh's approved use and durable efficacy in adults, Lilly plans to submit these data to global regulators to support a potential label expansion for pediatric ulcerative colitis More than 80% of patients responded to Omvoh induction, and half of responders, ages 6…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishA positive Phase 3 result opens a potential label expansion for a key Lilly drug.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Lilly announced positive one-year results from the Phase 3 SHINE-2 study of Omvoh.
- 02More than 80% of patients responded to Omvoh induction.
- 03Lilly plans to submit the data to global regulators.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets